Emerging new anticancer therapies in 2013.
Year 2013 has been rich in presentations and publications about new emerging anticancer agents, both in peer-review journals and in international meetings such as American Society of Clinical Oncology (ASCO), European Cancer Congress (European Cancer Organization - ECCO/European Society of Medical Oncology - ESMO), American Association for Cancer Research Meeting (AACR), Molecular Target and Cancer Therapeutics AACR-NCI-EORTC International Conference and Targeted Anticancer Therapies Meeting (TAT). Our purpose is to give an update in 2013's most important advances in new anticancer therapies. We will highlight recent advances in immunotherapy; combinations of targeted agents to overcome resistance; second and third generation of targeted agents against oncogene addiction and new antibody-drug conjugates against epithelial tumors. Future implications of this year's emerging therapies will probably lead to the approval of new immunotherapies for treatment of several tumor types and second-generation agents to overcome resistance in those tumors with oncogene addiction.